Abstract Number: 0293 • ACR Convergence 2022
Long-term Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs: Results Through 5 Years from SELECT-BEYOND
Background/Purpose: The primary treatment goal for patients with rheumatoid arthritis (RA) is sustained remission (REM), but low disease activity (LDA) is considered an appropriate target…Abstract Number: 2014 • ACR Convergence 2022
Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up
Background/Purpose: Difficult-to-Treat Rheumatoid Arthritis (RA) (D2T), is a concept recently defined by EULAR, it refers to patients who do not achieve the therapeutic target, who…Abstract Number: 0294 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study
Background/Purpose: To evaluate the long-term efficacy and safety of upadacitinib (UPA) over 5 yrs among patients with rheumatoid arthritis (RA) in a long-term extension (LTE)…Abstract Number: 2110 • ACR Convergence 2022
Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic…Abstract Number: 0295 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-NEXT Study
Background/Purpose: In the phase 3 SELECT-NEXT study, upadacitinib (UPA) demonstrated efficacy at wk 12 and sustained efficacy up to wk 60 in patients with rheumatoid…Abstract Number: 2139 • ACR Convergence 2022
Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial
Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…Abstract Number: 0348 • ACR Convergence 2022
Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis
Background/Purpose: Cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE), can be debilitating and cause significant scarring and psychological distress. Belimumab, a monoclonal…Abstract Number: 0417 • ACR Convergence 2022
Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Literature Review
Background/Purpose: The ASAS-SPEAR (SPondyloarthritis EARly definition) project aims to develop a consensual definition of early SpA. Therefore, it is important to know whether treatment earlier…Abstract Number: 0474 • ACR Convergence 2022
Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients
Background/Purpose: Tocilizumab (TCZ) has shown to be useful in the treatment of large-vessel vasculitis, including giant cell arteritis (GCA). There is general agreement on the…Abstract Number: 0851 • ACR Convergence 2022
Responsiveness of Patient-Reported Physical Function Measures in Juvenile Arthritis
Background/Purpose: The ACR Pediatric Criteria (ACR Pedi) contains a core set of outcome variables, including a measure of functional ability, to evaluate improvement over time…Abstract Number: 0923 • ACR Convergence 2022
Identification of Cell-Specific DNA Methylation Changes Associated with MTX Treatment Response in Rheumatoid Arthritis
Background/Purpose: MTX is the recommended first treatment for rheumatoid arthritis (RA); however, only ~40% respond adequately to MTX. Significant joint damage can occur in the…Abstract Number: 1019 • ACR Convergence 2022
Association Between Stringent Clinical Measures of Disease Activity and Clinically Meaningful Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: Results from KEEPsAKE 1 and 2 Clinical Trials
Background/Purpose: Assessment of disease activity in PsA patients is important to evaluate therapeutic response in clinical trials. Patient-reported outcomes (PROs) are evaluated to assess benefits…Abstract Number: 1079 • ACR Convergence 2022
Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Study of 28 Cases from a Single Univeristary Hospital
Background/Purpose: Anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyarteritis (MPA). Standard treatment is…Abstract Number: 1147 • ACR Convergence 2022
Transcriptomic Changes Induced by Tocilizumab in Ex-Vivo PBMCs from Patients with GCA in Remission. Predictors of Response
Background/Purpose: Glucocorticoids (GCs) are only effective therapy able to induce disease remission, but most patients relapse when GC are tapered and suffer from GC-related toxicity.…Abstract Number: 1362 • ACR Convergence 2022
Validation of the 2016 ACR/EULAR Myositis Response Criteria in Juvenile Dermatomyositis (JDM) Clinical Trials and Consensus Profiles
Background/Purpose: Juvenile dermatomyositis (JDM) ACR-EULAR myositis response criteria (MRC) were developed based on absolute % changes in 6 core set measures (CSM) differentially weighted to…